ストックスクリーナーアプリを入手
4.75
1.28%
0.06
プレマーケット:
4.71
-0.04
-0.84%
Arbutus Biopharma Corp (ABUS) 最新ニュース
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals
Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS: Key Developments and Market Impact - GuruFocus
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars - Benzinga
Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia
Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Bloomberg.com
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Moderna Shares Rise 16% After Company Enters Settlement Agreement With Arbutus Biopharma, Genevant Sciences - Bitget
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive
Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle - GuruFocus
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna - TipRanks
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement - Investing.com
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna - StreetInsider
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case - Stock Titan
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI
Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial - IPWatchdog.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Two Seas Capital reports 6.5% Arbutus Biopharma (ABUS) ownership - Stock Titan
What insider trading reveals about Arbutus Biopharma Corporation stockMarket Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Will Arbutus Biopharma Corporation stock remain a Wall Street favorite2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Moving Averages: How does Arbutus Biopharma Corporation correlate with NasdaqWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Court narrows but sustains Arbutus (NASDAQ: ABUS) patent claims in Moderna COVID-19 vaccine fight - Stock Titan
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.8%What's Next? - MarketBeat
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Rises on Patent Dispute Jury Trial Deci - GuruFocus
Arbutus Biopharma (ABUS) Shares Surge Amid Market Fluctuations - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Traders Buy Large Volume of Call Options on Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Aug Drivers: Can Arbutus Biopharma Corporation ride the EV waveQuarterly Investment Review & Consistent Return Strategy Ideas - baoquankhu1.vn
Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Aug Closing: Should I buy Arbutus Biopharma Corporation stock nowJuly 2025 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O - GuruFocus
Arbutus Biopharma (ABUS) Faces Patent Revocation in Europe - GuruFocus
ABUS Stock Tumbles on European Patent Revocation - StocksToTrade
Arbutus Biopharma (ABUS) Shares Drop Amid Patent Revocation - GuruFocus
Market Dynamics Cause Shifts for Arbutus Biopharma - StocksToTrade
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash - Intellectia AI
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Arbutus (ABUS) upgraded to buy: Here's what you should know - MSN
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Arbutus Biopharma Shares Fall 19% On European Patent Revocation - Nasdaq
Arbutus Biopharma (ABUS) Patent Revocation Leads to 14% Pre-Market Drop - Intellectia AI
European Patent Office revokes Arbutus Biopharma patent following appeal - Investing.com
Arbutus Biopharma CorpEPO revokes Arbutus Biopharma's European patent EP 2279254SEC filing - marketscreener.com
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? - Stocktwits
Weekly Trades: Will Arbutus Biopharma Corporation stock gain from lower inflationTrade Signal Summary & Stock Market Timing Techniques - Bộ Nội Vụ
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How sustainable is Arbutus Biopharma Corporation stock dividend payoutBear Alert & Safe Entry Momentum Stock Tips - Улправда
Why Arbutus Biopharma Corporation stock is popular among millennialsQuarterly Portfolio Summary & Long-Term Growth Plans - Улправда
New Highs: Why Arbutus Biopharma Corporation stock is popular among millennialsEarnings Miss & Growth-Oriented Investment Plans - Улправда
What is the fair value of Arbutus Biopharma Corporation stock nowWeekly Trading Summary & Weekly Momentum Picks - Улправда
Will Arbutus Biopharma Corporation stock deliver shareholder valueWeekly Market Report & Fast Entry Momentum Alerts - Улправда
How Arbutus Biopharma Corporation stock reacts to Fed rate cutsQuarterly Portfolio Summary & Weekly High Momentum Picks - Улправда
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):